Navigation Links
Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
Date:11/12/2009

or the Nine Months For the Three Months Ended September 30, Ended September 30, 2009 2008 2009 2008 ---- ---- ---- ---- Revenues $- $- $- $- Operating costs and expenses: Research and development 850,998 2,451,579 4,549,883 5,438,082 General and administrative 441,316 463,199 1,555,786 1,664,405 ----------- ------------ ------------ ------------ Total operating costs and expenses 1,292,314 2,914,778 6,105,669 7,102,487 ----------- ------------ ------------ ------------ Loss from operations (1,292,314) (2,914,778) (6,105,669) (7,102,487) Interest income 5,594 59,418 25,861 285,640 ----------- ------------ ------------ ------------ Loss before income taxes (1,286,720) (2,855,360) (6,079,808) (6,816,847) Provision for income taxes - - - - ----------- ------------ ------------ ------------ Net loss $(1,286,720) $(2,855,360) $(6,079,808) $(6,816,847) =========== ============ ============ ============ Loss per share - basic and diluted $(0.09) $(0.22) $(0.43) $(0.54) =========== ============ ============ ============ Weighted average shares outstanding - basic and diluted 14,065,385 12,863,196 14,065,385 12,661,859 =========== ============ ============ ============
                         CATALYST PHARMACEUTI
'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.C. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Medical Equipment, Inc. for the third straight year, ... Inc. 500|5000, an exclusive ranking of the nation,s ... comprehensive look at the most important segment of ... Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and ...
(Date:8/21/2014)... 21, 2014  Seventy-one percent of Americans believe the abuse ... serious public health and safety issue in the ... released today by Repass & Partners, a Cincinnati ... understand the severity of the prescription medication abuse problem and ... very serious health situation facing our country," Rex Repass ...
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
... (Nasdaq: MYL ) today announced that Mylan ... a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor ... connection with Mylan Specialty,s Abbreviated New Drug Application (ANDA) ... 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex® 2
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... to be filed in U.S. courts on behalf ... due to their use of prescription low testosterone ... documents, a new claim was filed against Pfizer ... who allegedly suffered life-threatening heart issues due to ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... Ultrasound and Management Practice Software to Support Advanced Diagnoses ... ... Oct. 21 South Carolina Veterinary,Specialists (SCVS), a leading regional ... Digital Practice(R) at its,new state-of-the-art facility in Columbia. The Eklin ...
... EXTON, Pa., Oct. 21 Isolagen(TM), Inc. (Amex:,ILE) ... in the Phase,II/III Study IT-A-008 investigating Isolagen Therapy(TM) ... scars. Further, approximately half of all,of the study ... the acne study will conclude in the first ...
... Is Safe And Active in Recurrent Ovarian Cancer; ... Oct. 21 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... results of the company,s proprietary polymer DACH,platinum prodrug, ... this week at a major international oncology conference ...
... reserve compensates for brain damage, study says , , TUESDAY, ... of education and a mentally demanding job may help ... according to an Italian study. , It included 242 ... 144 with no memory problems. People with mild cognitive ...
... players reach the base faster that way , , TUESDAY, Oct. ... slide head first or feet first during Wednesday,s first game ... a physicist instead of a coach. , The effectiveness of ... and factors like a baseball player,s center of gravity, explained ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
Cached Medicine News:Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 2Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 3Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 2Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 3Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 3Health News:Job, Education May Buffer Against Dementia 2Health News:Head-First Slide a Heads-Up Play 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3
Calibration plasmas for Assays of Low Molecular Weight Heparins (LMWH)using the Anti-Xa method on STA© Analyzers....
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: